[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S Hofman , Louise Emmett , Shahneen Sandhu , Amir Iravani
The Lancet 397 ( 10276) 797 -804
350
2021
Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer.
Niranjan Sathianathen , Patricia Bukczynska , Carmel Pezaro , Kate Mahon
Translational Andrology and Urology 10 ( 4) 1688 -1699
2021
Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assay
Heidi Fettke , Jason A Steen , Edmond M Kwan , Patricia Bukczynska
BioTechniques 69 ( 2) 133 -140
2020
Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the phase 2 ICE-PAC clinical trial
Edmond M Kwan , Lavinia Spain , Angelyn Anton , Chun L Gan
European Urology 81 ( 3) 253 -262
22
2022
Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context
Michael P Kolinsky , Karen Y Niederhoffer , Edmond M Kwan , Sebastien J Hotte
Canadian Urological Association Journal 16 ( 4) 132
1
2022
Relationship between circulating lipids and cytokines in metastatic castration-resistant prostate cancer
Hui-Ming Lin , Nicole Yeung , Jordan F Hastings , David R Croucher
Cancers 13 ( 19) 4964
12
2021
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer
Blossom Mak , Hui-Ming Lin , Edmond M Kwan , Heidi Fettke
BMC medicine 20 ( 1) 1 -14
6
2022
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?
Amanda Pereira-Salgado , Angelyn Anton , Fanny Franchini , Robert K Mahar
Expert Review of Pharmacoeconomics & Outcomes Research 23 ( 2) 231 -239
2
2023
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Karim Fizazi , Margitta Retz , Daniel P Petrylak , Jeffrey C Goh
Journal for immunotherapy of cancer 10 ( 8)
24
2022
Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer
Angelyn Anton , Sruti Pillai , Marie Christine Semira , Shirley Wong
BJUI compass 3 ( 3) 205 -213
8
2022
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer–an Australian multi-centre observational study
Angelyn Anton , Shirley Wong , Julia Shapiro , Andrew Weickhardt
European Journal of Cancer 157 485 -492
8
2021
Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis
Grace Chazan , Angelyn Anton , Shirley Wong , Julia Shapiro
Asia‐Pacific Journal of Clinical Oncology 18 ( 6) 642 -649
3
2022
Prostate‐specific membrane antigen positron emission tomography‐computed tomography use prior to systemic therapy in metastatic castration‐resistant prostate cancer.
Richard Kelly , Andrew Jensen , Nathasha Karunaratna , Shirley Wong
BJU international 131 ( 2)
1
2023
Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
Nathasha Karunaratna , Andrew Jensen , Shirley Wong , Julia Shapiro
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 16 58 -58
2020
Independent prognostic impact of plasma NCOA2 alterations in metastatic castration‐resistant prostate cancer
Heidi Fettke , Edmond M Kwan , Patricia Bukczynska , Jason A Steen
The Prostate 81 ( 13) 992 -1001
4
2021
Multi-omic integration of blood-based tumor-associated genomic and lipidomic profiles using machine learning models in metastatic prostate cancer
Shikai Fang , Shandian Zhe , Hui-Ming Lin , Arun A Azad
JCO Clinical Cancer Informatics 7 e2300057 -e2300057
2
2023
Phase I/II trial of the combination of 177lutetium prostate specific membrane antigen 617 and idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN)
Megan Crumbaker , Sarennya Pathmanandavel , Andrew O Yam , Andrew Nguyen
European urology oncology 4 ( 6) 963 -970
30
2021
Impact of granulocyte-colony stimulating factor on bleomycin-induced pneumonitis in chemotherapy-treated germ cell tumors
Edmond M Kwan , Sophie Beck , Eitan Amir , Michael A Jewett
Clinical Genitourinary Cancer 16 ( 1) e193 -e199
20
2018
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
James P Buteau , Andrew J Martin , Louise Emmett , Amir Iravani
The Lancet Oncology 23 ( 11) 1389 -1397
107
2022
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology
Gail P Risbridger , Ashlee K Clark , Laura H Porter , Roxanne Toivanen
Nature communications 12 ( 1) 5049 -5049
46
2021